{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:18:26Z","timestamp":1761862706429},"reference-count":35,"publisher":"Cambridge University Press (CUP)","issue":"6","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Nutr"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:p>The effect of diet<jats:italic>v<\/jats:italic>. statins on LDL particle size as a risk factor for CVD has not been examined. We compared, in the same subjects, the impact of a dietary portfolio of cholesterol-lowering foods and a statin on LDL size electrophoretic characteristics. Thirty-four hyperlipidaemic subjects completed three 1-month treatments as outpatients in random order: a very-low saturated fat diet (control); the same diet with 20\u00a0mg lovastatin; a dietary portfolio high in plant sterols (1\u00a0g\/4200\u00a0kJ), soya proteins (21\u00b74\u00a0g\/4200\u00a0kJ), soluble fibres (9\u00b78\u00a0g\/4200\u00a0kJ) and almonds (14\u00a0g\/4200\u00a0kJ). LDL electrophoretic characteristics were measured by non-denaturing polyacrylamide gradient gel electrophoresis of fasting plasma at 0, 2 and 4 weeks of each treatment. The reductions in plasma LDL-cholesterol levels with the dietary portfolio and with statins were comparable and were largely attributable to reductions in the estimated concentration of cholesterol within the smallest subclass of LDL (portfolio \u2212\u00a00\u00b769\u00a0(<jats:sc>se<\/jats:sc>0\u00b710) mmol\/l, statin \u2212\u00a00\u00b799 (<jats:sc>se<\/jats:sc>0\u00b710) mmol\/l). These were significantly greater (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b701) than changes observed after the control diet (\u00a0\u2212\u00a00\u00b717 (<jats:sc>se<\/jats:sc>0\u00b708) mmol\/l). Finally, baseline C-reactive protein levels were a significant predictor of the LDL size responsiveness to the dietary portfolio but not to the other treatments. The dietary portfolio, like the statin treatment, had only minor effects on several features of the LDL size phenotype, but the pronounced reduction in cholesterol levels within the small LDL fraction may provide additional cardiovascular benefit over the traditional low-fat diet of National Cholesterol Education Program Step II.<\/jats:p>","DOI":"10.1017\/s0007114507781461","type":"journal-article","created":{"date-parts":[[2007,7,30]],"date-time":"2007-07-30T13:37:34Z","timestamp":1185802654000},"page":"1229-1236","source":"Crossref","is-referenced-by-count":24,"title":["Comparison of a dietary portfolio diet of cholesterol-lowering foods and a statin on LDL particle size phenotype in hypercholesterolaemic participants"],"prefix":"10.1017","volume":"98","author":[{"given":"Iris","family":"Gigleux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J. A.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyril W. C.","family":"Kendall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augustine","family":"Marchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothea A.","family":"Faulkner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia M. W.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azadeh","family":"Emam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina L.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke A.","family":"Trautwein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen G.","family":"Lapsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip W.","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beno\u00eet","family":"Lamarche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2007,12,1]]},"reference":[{"key":"S0007114507781461_ref18","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/74.1.72"},{"key":"S0007114507781461_ref25","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/73.2.225"},{"key":"S0007114507781461_ref5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Anon","year":"2002","journal-title":"Lancet"},{"key":"S0007114507781461_ref27","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/80.5.1185"},{"key":"S0007114507781461_ref2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.1.69"},{"key":"S0007114507781461_ref1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0022-2275(20)38178-5","article-title":"Identification of multiple subclasses of plasma low density lipoproteins in normal humans","volume":"23","author":"Krauss","year":"1982","journal-title":"J Lipid Res"},{"key":"S0007114507781461_ref4","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"S0007114507781461_ref23","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/76.1.57"},{"key":"S0007114507781461_ref28","doi-asserted-by":"publisher","DOI":"10.1079\/BJN20041241"},{"key":"S0007114507781461_ref14","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/69.4.632"},{"key":"S0007114507781461_ref31","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/135.5.1075"},{"key":"S0007114507781461_ref34","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000052939.59093.45"},{"key":"S0007114507781461_ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486"},{"key":"S0007114507781461_ref3","doi-asserted-by":"publisher","DOI":"10.1161\/hc4401.098490"},{"key":"S0007114507781461_ref30","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000080288.30567.86"},{"key":"S0007114507781461_ref6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJM198807073190105","article-title":"HMG-CoA reductase inhibitors for treatment of hypercholesterolemia","volume":"319","author":"Grundy","year":"1988","journal-title":"N Engl J Med"},{"key":"S0007114507781461_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(91)90054-Z"},{"key":"S0007114507781461_ref22","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/134.3.574"},{"key":"S0007114507781461_ref29","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/136.4.1005"},{"key":"S0007114507781461_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(91)90283-I"},{"key":"S0007114507781461_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(91)90017-W"},{"key":"S0007114507781461_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(02)00052-7"},{"key":"S0007114507781461_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(02)00037-0"},{"key":"S0007114507781461_ref11","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.15.1942"},{"key":"S0007114507781461_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00288-9"},{"key":"S0007114507781461_ref16","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.18.2284"},{"key":"S0007114507781461_ref17","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn.81.2.380"},{"key":"S0007114507781461_ref19","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/134.3.592"},{"key":"S0007114507781461_ref20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejcn.1602142"},{"key":"S0007114507781461_ref21","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/76.2.351"},{"key":"S0007114507781461_ref24","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/71.6.1462"},{"key":"S0007114507781461_ref26","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejcn.1602106"},{"key":"S0007114507781461_ref32","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejcn.1602152"},{"key":"S0007114507781461_ref33","doi-asserted-by":"publisher","DOI":"10.1053\/meta.2002.35578"},{"key":"S0007114507781461_ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(99)00463-3"}],"container-title":["British Journal of Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007114507781461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T19:32:47Z","timestamp":1629487967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007114507781461\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S0007114507781461"],"URL":"https:\/\/doi.org\/10.1017\/s0007114507781461","relation":{},"ISSN":["0007-1145","1475-2662"],"issn-type":[{"value":"0007-1145","type":"print"},{"value":"1475-2662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}